EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+55.36%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$750M
AUM Growth
+$187M
Cap. Flow
+$114M
Cap. Flow %
15.17%
Top 10 Hldgs %
73.32%
Holding
52
New
16
Increased
12
Reduced
5
Closed
13
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.7 years
Top 20 Avg Time Held Equity + Options
0.6 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
0.6 years

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$28.5M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$28M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$22M
4
ASND icon
Ascendis Pharma A/S
ASND
+$17.9M
5
KURA icon
Kura Oncology
KURA
+$16.3M

Top Sells

Rank Stock Value
1
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$29.5M
2
SGMO icon
SANGAMO THERAPEUTICS INC
SGMO
+$25.9M
3
EDIT icon
Editas Medicine
EDIT
+$12M
4
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$4.52M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$3.41M

Sector Composition

Rank Sector Weight
1 Healthcare 97.33%
2 Miscellaneous 2.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ASMB icon
1
Assembly Biosciences
ASMB
$418M
$103M 13.7%
245,264
– –
2014 Q4
11 quarters
KYNB icon
2
Kyntra Bio
KYNB
$22.6M
$93.4M 12.45%
69,427
+6,009
+9% +$6.33M
2014 Q4
11 quarters
IRWD icon
3
Ironwood Pharmaceuticals
IRWD
$595M
$86.1M 11.47%
6,518,742
+2,036,902
+45% +$28M
2015 Q4
7 quarters
ASND icon
4
Ascendis Pharma A/S
ASND
$14.9B
$76.4M 10.18%
2,107,600
+625,000
+42% +$17.9M
2016 Q3
4 quarters
KURA icon
5
Kura Oncology
KURA
$855M
$56.3M 7.51%
3,766,852
+1,733,230
+85% +$16.3M
2015 Q4
7 quarters
IMMU
6
DELISTED
Immunomedics Inc
IMMU
$40M 5.33%
+2,860,019
New +$28.5M
2017 Q3
0 quarters
MYOK
7
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$29.6M 3.94%
+689,986
New +$22M
2017 Q3
0 quarters
LKFT icon
8
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
$24.5M 3.27%
240,776
-337,729
-58% -$29.5M
2015 Q4
7 quarters
MRNS icon
9
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$21.3M 2.83%
+905,568
New +$10.2M
2017 Q3
0 quarters
ATYR icon
10
aTyr Pharma
ATYR
$18M
$19.9M 2.65%
281,061
+117,300
+72% +$5.43M
2016 Q4
3 quarters
FBRX icon
11
DELISTED
Forte Biosciences
FBRX
$18.7M 2.49%
4,006
– –
2017 Q2
1 quarter
ARRY icon
12
DELISTED
Array Biopharma Inc
ARRY
$15.4M 2.05%
+1,250,000
New +$11.6M
2017 Q3
0 quarters
CTMX icon
13
CytomX Therapeutics
CTMX
$486M
$15.1M 2.01%
829,771
+34,802
+4% +$543K
2017 Q1
2 quarters
CRVS icon
14
Corvus Pharmaceuticals
CRVS
$789M
$14.5M 1.93%
908,525
+103,525
+13% +$1.43M
2017 Q2
1 quarter
INDP icon
15
Indaptus Therapeutics
INDP
$294M
$13.4M 1.79%
+670
New +$9.66M
2017 Q3
0 quarters
INSM icon
16
Insmed
INSM
$21.4B
$12.7M 1.69%
+405,400
New +$7.72M
2017 Q3
0 quarters
WVE icon
17
Wave Life Sciences
WVE
$609M
$12.3M 1.64%
+564,248
New +$11.3M
2017 Q3
0 quarters
CASC
18
DELISTED
Cascadian Therapeutics, Inc.
CASC
$12.3M 1.64%
3,000,000
– –
2017 Q1
2 quarters
VRTX icon
19
CALL
Vertex Pharmaceuticals
VRTX
$126B
$10.3M 1.37%
67,600
+7,600
+13% +$1.14M
2017 Q2
1 quarter
IRWD icon
20
CALL
Ironwood Pharmaceuticals
IRWD
$595M
$9.78M 1.3%
+740,280
New +$10.2M
2017 Q3
0 quarters
OMER icon
21
Omeros
OMER
$1.33B
$9.73M 1.3%
+450,000
New +$9.53M
2017 Q3
0 quarters
FATE icon
22
Fate Therapeutics
FATE
$232M
$8.96M 1.19%
2,262,678
-274,348
-11% -$933K
2017 Q1
2 quarters
RGLS icon
23
DELISTED
Regulus Therapeutics
RGLS
$6.55M 0.87%
43,660
+12,750
+41% +$1.6M
2017 Q1
2 quarters
DRNA
24
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$5.51M 0.73%
957,992
+190,000
+25% +$691K
2017 Q1
2 quarters
TPST icon
25
Tempest Therapeutics
TPST
$10.7M
$4.99M 0.66%
1,201
– –
2017 Q1
2 quarters
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2017 Portfolio in Review

As of Q3 2017, EcoR1 Capital held 52 positions worth $750M, up 33% from $563M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

EcoR1 Capital deployed $114M of net new capital in Q3 2017, opening 16 new positions and adding to 12 existing holdings. Its largest new stake was Immunomedics Inc: 2,860,019 shares worth $40M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 77% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $29.5M trimmed.

  • EcoR1 Capital's largest Q3 2017 buy was Immunomedics Inc: 2,860,019 shares worth $40M.
  • EcoR1 Capital added most to Ironwood Pharmaceuticals in Q3 2017, an estimated $28M increase.
  • EcoR1 Capital's biggest Q3 2017 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $29.5M.
  • EcoR1 Capital fully exited Editas Medicine in Q3 2017, selling an estimated $12M.
  • EcoR1 Capital's ten largest holdings make up 73% of its $750M portfolio in Q3 2017.
  • EcoR1 Capital opened 16 new positions and closed 13 in Q3 2017.
  • EcoR1 Capital's portfolio value rose 33% quarter-over-quarter to $750M.

Based on EcoR1 Capital's 13F filing for Q3 2017, filed 14 Nov 2017.